RB-190 / Suven Life Sci - LARVOL DELTA

Company repurposing anticancer medication RB-190 for Parkinson’s (Parkinson's News Today) - "Right Brain Bio is repurposing the approved therapy RB-190 as a treatment for Parkinson’s disease — and is now preparing to seek U.S. Food and Drug Administration (FDA) clearance to test the anticancer medication for this indication in a Phase 2 clinical trial...The company intends to file an application with the FDA asking for a green light to evaluate the therapy’s efficacy in slowing disease progression in Parkinson’s patients."

New P2 trial • Parkinson's Disease

In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson’s Disease (PRNewswire) - "Right Brain Bio...today announced a manufacturing agreement with Suven Pharmaceuticals...for the production of its lead drug candidate, RB-190, targeting the root cause of Parkinson's disease....RB-190 represents a groundbreaking approach to Parkinson's disease, aiming to modify the disease progression rather than merely alleviating symptoms."

Commercial • Parkinson's Disease